Low plasma DHEA-S increases mortality risk among male hemodialysis patients

Experimental Gerontology

Volumn 47, Issue 12, 2012, Pages 950-957

  Hsu, Heng Jung ^a,b   Yen, Chiung Hui ^c   Chen, Chih Ken ^a,b   Hsu, Kuang Hung ^b   Hsiao, Cheng Cheng ^a,b   Lee, Chin Chan ^a,b   Wu, I Wen ^a,b   Sun, Chiao Yin ^a,b   Chou, Chia Chi ^a,b   Hsieh, Ming Fang ^a,b   Chen, Chun Yu ^a,b   Hsu, Chiao Ying ^a,b   Tsai, Chi Jen ^a,b   Wu, Mai Szu ^a,b,c,d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular disease; Chronic kidney disease; Dehydroepiandrosterone sulfate; Hemodialysis; Mortality

Indexed keywords

ALBUMIN; CREATININE; PRASTERONE SULFATE;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84868302071     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2012.08.012     Document Type: Article

References (40)

1. Abadie J.M., Wright B., Correa G., Browne E.S., Porter J.R., Svec F. Effect of dehydroepiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat. The Obesity Research Program. Diabetes 1993, 42:662-669.
2. Altman R., Motton D.D., Kota R.S., Rutledge J.C. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul. Pharmacol. 2008, 48:76-84.
3. Barrett-Connor E., Khaw K.T., Yen S.S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N. Engl. J. Med. 1986, 315:1519-1524.
4. Carrero J.J., Qureshi A.R., Parini P., Arver S., Lindholm B., Barany P., Heimburger O., Stenvinkel P. Low serum testosterone increases mortality risk among male dialysis patients. J. Am. Soc. Nephrol. 2009, 20:613-620.
5. Daynes R.A., Araneo B.A., Dowell T.A., Huang K., Dudley D. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J. Exp. Med. 1990, 171:979-996.
6. De Pergola G., Cospite M.R., Giagulli V.A., Giorgino F., Garruti G., Cignarelli M., Giorgino R. Insulin-like growth factor-1 (IGF-1) and dehydroepiandrosterone sulphate in obese women. Int. J. Obes. Relat. Metab. Disord. 1993, 17:481-483.
7. De Pergola G., Triggiani V., Giorgino F., Cospite M.R., Garruti G., Cignarelli M., Guastamacchia E., Giorgino R. The free testosterone to dehydroepiandrosterone sulphate molar ratio as a marker of visceral fat accumulation in premenopausal obese women. Int. J. Obes. Relat. Metab. Disord. 1994, 18:659-664.
8. Ebeling P., Koivisto V.A. Physiological importance of dehydroepiandrosterone. Lancet 1994, 343:1479-1481.
9. Enomoto M., Adachi H., Fukami A., Furuki K., Satoh A., Otsuka M., Kumagae S., Nanjo Y., Shigetoh Y., Imaizumi T. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru study). J. Am. Geriatr. Soc. 2008, 56:994-998.
10. Glei D.A., Goldman N. Dehydroepiandrosterone sulfate (DHEAS) and risk for mortality among older Taiwanese. Ann. Epidemiol. 2006, 16:510-515.
11. Glei D.A., Goldman N., Weinstein M., Liu I.W. Dehydroepiandrosterone sulfate (DHEAS) and health: does the relationship differ by sex?. Exp. Gerontol. 2004, 39:321-331.
12. Goldman N., Glei D.A. Sex differences in the relationship between DHEAS and health. Exp. Gerontol. 2007, 42:979-987.
13. Goodkin D.A., Bragg-Gresham J.L., Koenig K.G., Wolfe R.A., Akiba T., Andreucci V.E., Saito A., Rayner H.C., Kurokawa K., Port F.K., Held P.J., Young E.W. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J. Am. Soc. Nephrol. 2003, 14:3270-3277.
14. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., Wang Y., Chung J., Emerick A., Greaser L., Elashoff R.M., Salusky I.B. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000, 342:1478-1483.
15. Guevara A., Vidt D., Hallberg M.C., Zorn E.M., Pohlman C., Wieland R.G. Serum gonadotropin and testosterone levels in uremic males undergoing intermittent dialysis. Metabolism 1969, 18:1062-1066.
16. Gungor O., Kircelli F., Carrero J.J., Asci G., Toz H., Tatar E., Hur E., Sever M.S., Arinsoy T., Ok E. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?. Clin. J. Am. Soc. Nephrol. 2010, 5:2018-2023.
17. Handelsman D.J., Dong Q. Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol. Metab. Clin. North Am. 1993, 22:145-161.
18. Hennebold J.D., Daynes R.A. Regulation of macrophage dehydroepiandrosterone sulfate metabolism by inflammatory cytokines. Endocrinology 1994, 135:67-75.
19. Holdsworth S., Atkins R.C., de Kretser D.M. The pituitary-testicular axis in men with chronic renal failure. N. Engl. J. Med. 1977, 296:1245-1249.
20. I.NKF-K/DOQI Clinica l Practice Guidelines for Hemodialysis Adequacy: update 2000. Am J Kidney Dis 2001, 37:S7-S64.
21. Inaudi P., De Leo V., De Leo M., Verzetti G., D'Antona N., Genazzani A.R. Changes in plasma concentrations of adrenal androgens in patients with chronic renal insufficiency. Boll. Soc. Ital. Biol. Sper. 1983, 59:1861-1867.
22. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Kurioka S., Yano S., Sugimoto T. Serum DHEA-S level is associated with the presence of atherosclerosis in postmenopausal women with type 2 diabetes mellitus. Endocr. J. 2008, 55:667-675.
23. Khaw K.T., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007, 116:2694-2701.
24. Levey A.S., Andreoli S.P., DuBose T., Provenzano R., Collins A.J. Chronic kidney disease: common, harmful, and treatable-World Kidney Day 2007. Clin. J. Am. Soc. Nephrol. 2007, 2:401-405.
25. Mastrogiacomo I., De Besi L., Zucchetta P., Serafini E., La Greca G., Gasparotto M.L., Lorenzi S., Dean P. Male hypogonadism of uremic patients on hemodialysis. Arch. Androl. 1988, 20:171-175.
26. Mazat L., Lafont S., Berr C., Debuire B., Tessier J.F., Dartigues J.F., Baulieu E.E. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8145-8150.
27. Meikle A.W., Dorchuck R.W., Araneo B.A., Stringham J.D., Evans T.G., Spruance S.L., Daynes R.A. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J. Steroid Biochem. Mol. Biol. 1992, 42:293-304.
28. Mitchell L.E., Sprecher D.L., Borecki I.B., Rice T., Laskarzewski P.M., Rao D.C. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation 1994, 89:89-93.
29. Nieszporek T., Witkowicz J., Nowak L., Chudek J., Wiecek A. Low plasma dehydroepiandrosterone sulfate level and its relationship to adiponectin in hemodialysis patients. Ren. Fail. 2007, 29:417-421.
30. Plager J.E. The binding of androsterone sulfate, ethiocholanolone sulfate, and dehydroisoandrosterone sulfate by human plasma protein. J. Clin. Invest. 1965, 44:1234-1239.
31. Poynter M.E., Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 1998, 273:32833-32841.
32. Rice T., Sprecher D.L., Borecki I.B., Mitchell L.E., Laskarzewski P.M., Rao D.C. Cincinnati myocardial infarction and hormone family study: family resemblance for testosterone in random and MI families. Am. J. Med. Genet. 1993, 47:542-549.
33. Shufelt C., Bretsky P., Almeida C.M., Johnson B.D., Shaw L.J., Azziz R., Braunstein G.D., Pepine C.J., Bittner V., Vido D.A., Stanczyk F.Z., Bairey Merz C.N. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J. Clin. Endocrinol. Metab. 2010.
34. Stewart-Bentley M., Gans D., Horton R. Regulation of gonadal function in uremia. Metabolism 1974, 23:1065-1072.
35. Straub R.H., Vogl D., Gross V., Lang B., Scholmerich J., Andus T. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am. J. Gastroenterol. 1998, 93:2197-2202.
36. Trivedi D.P., Khaw K.T. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J. Clin. Endocrinol. Metab. 2001, 86:4171-4177.
37. Vasdev S., Johnson E., Longerich L., Prabhakaran V.M., Gault M.H. Plasma endogenous digitalis-like factors in healthy individuals and in dialysis-dependent and kidney transplant patients. Clin. Nephrol. 1987, 27:169-174.
38. Webb S.J., Geoghegan T.E., Prough R.A., Michael Miller K.K. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab. Rev. 2006, 38:89-116.
39. Weinhandl E.D., Foley R.N., Gilbertson D.T., Arneson T.J., Snyder J.J., Collins A.J. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J. Am. Soc. Nephrol. 2010, 21:499-506.
40. Zumoff B., Walter L., Rosenfeld R.S., Strain J.J., Degen K., Strain G.W., Levin J., Fukushima D. Subnormal plasma adrenal androgen levels in men with uremia. J. Clin. Endocrinol. Metab. 1980, 51:801-805.